ALBPS.PA · Biophytis SA

-

Please sign in to comment on ALBPS.PA

1 Comment

Admin

4 years, 10 months ago

Biophytis SA is currently in a long term downtrend where the price is trading 23.2% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Its net income has dropped by 0.0% to $-4M since the same quarter in the previous year.

Finally, its free cash flow fell by 106.6% to $-5M since the same quarter in the previous year.

Based on the above factors, Biophytis SA gets an overall score of 1/5.

Exchange	PA
CurrencyCode	EUR
ISIN	FR0012816825
Sector	Healthcare
Industry	Biotechnology

PE Ratio	None
Beta	0.29
Target Price	2.2
Market Cap	2M
Dividend Yield	None

ABOUT

Biophytis SA

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

ALBPS.PA · Biophytis SA

-

Biophytis SA

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Biophytis SA using a moving average strategy